BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
作者： T Yokota , T Ura , N Shibata , D Takahari , K Shitara
DOI: 10.1038/BJC.2011.19
关键词:
摘要: Activating mutation of KRAS and BRAF are focused on as potential prognostic predictive biomarkers in patients with colorectal cancer (CRC) treated anti-EGFR therapies. This study investigated the clinicopathological features impact KRAS/BRAF advanced recurrent CRC patients. Patients systemic chemotherapy (n=229) were analysed for genotypes by cycleave PCR. Prognostic factors associated survival identified univariate multivariate analyses using Cox proportional hazards model. mutations present 34.5% 6.5% patients, respectively. mutated tumours more likely to develop right colon, be poorly differentiated adenocarcinoma or mucinous carcinoma, peritoneal metastasis. The median overall (OS) mutation-positive 13 was 11.0 27.7 months, respectively, which significantly worse than that wild-type (wt) (40.6 months) (BRAF; HR=4.25, P<0.001, KRAS13; HR=2.03, P=0.024). After adjustment significant regression analysis, poor OS (HR=4.23, P=0.019). Presence is one most powerful CRC. KRAS13 showed a trend towards
nature.com
researchgate.net 
sci-hub.se 参考文章(40)
S-C Wei, C-Y Yu, J-J Tsai-Wu, Y-N Su, J-C Sheu, C-HH Wu, C-Y Wang, J-M Wong, Low mutation rate of hMSH2 and hMLH1 in Taiwanese hereditary non-polyposis colorectal cancer. Clinical Genetics. ,vol. 64, pp. 243- 251 ,(2003) , 10.1034/J.1399-0004.2003.00123.X
Bert Vogelstein, Kenneth W. Kinzler, The Genetic Basis of Human Cancer ,(1997)
Terje Ahlquist, Irene Bottillo, Stine A. Danielsen, Gunn I. Meling, Torleiv O. Rognum, Guro E. Lind, Bruno Dallapiccola, Ragnhild A. Lothe, RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A Neoplasia. ,vol. 10, pp. 680- 686 ,(2008) , 10.1593/NEO.08312
S-C Lee, J-Y Guo, R Lim, R Soo, E Koay, M Salto-Tellez, A Leong, B-C Goh, Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia. Clinical Genetics. ,vol. 68, pp. 137- 145 ,(2005) , 10.1111/J.1399-0004.2005.00469.X
Koji Matsuzaki, Soichuro Miura, Guoren Deng, Sanjay Kakar, Young S. Kim, Hirofumi Tanaka, Vaibhav Sahai, Clinicopathologic Characteristics, CpG Island Methylator Phenotype, and BRAF Mutations in Microsatellite-Stable Colorectal Cancers Without Chromosomal Instability Archives of Pathology & Laboratory Medicine. ,vol. 132, pp. 958- 964 ,(2008) , 10.1043/1543-2165(2008)132[958:CCCIMP]2.0.CO;2
J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, J A Meyerhardt, Z Saridaki, V Georgoulias, D Finkelstein, C S Fuchs, M H Kulke, R A Shivdasani, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. ,vol. 101, pp. 465- 472 ,(2009) , 10.1038/SJ.BJC.6605164
Inti Zlobec, Michal Kovac, Priska Erzberger, Francesca Molinari, Michel P. Bihl, Alexander Rufle, Anja Foerster, Milo Frattini, Luigi Terracciano, Karl Heinimann, Alessandro Lugli, Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer. ,vol. 127, pp. 2569- 2575 ,(2010) , 10.1002/IJC.25265
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Yael Goldberg, Rinnat M. Porat, Inbal Kedar, Chen Shochat, Michal Sagi, Avital Eilat, Suzan Mendelson, Tamar Hamburger, Aviram Nissan, Ayala Hubert, Luna Kadouri, Eli Pikarski, Israela Lerer, Dvorah Abeliovich, Dani Bercovich, Tamar Peretz, Mutation spectrum in HNPCC in the Israeli population. Familial Cancer. ,vol. 7, pp. 309- 317 ,(2008) , 10.1007/S10689-008-9191-Y
H Sakamoto, J Shimizu, Y Horio, R Ueda, T Takahashi, T Mitsudomi, Y Yatabe, Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. The Journal of Pathology. ,vol. 212, pp. 287- 294 ,(2007) , 10.1002/PATH.2165